Ultragenyx Pharmaceutical (RARE) EBT (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of EBT data on file, last reported at -$184.0 million in Q1 2026.

• On a quarterly basis, EBT fell 22.67% year-over-year to -$184.0 million in Q1 2026; TTM through Mar 2026 was -$599.2 million, a 10.4% decrease from a year earlier, with the FY2025 full-year figure at -$565.0 million, changed 0.36% from the prior year.
• EBT for Q1 2026 stood at -$184.0 million, down from -$121.7 million in the prior quarter.
• Over the last five years, EBT for RARE reached as high as -$114.0 million in Q2 2025 and fell as low as -$238.8 million in Q3 2022.
• Historically, EBT has averaged -$154.3 million across 5 years, with a median of -$153.3 million in 2022.
• Across the five-year window, EBT sank 227.98% in 2022 and surged 33.42% in 2023, its largest moves.
• Year by year, EBT stood at -$153.3 million in 2022, then climbed by 16.87% to -$127.4 million in 2023, then dropped by 1.09% to -$128.8 million in 2024, then advanced by 5.54% to -$121.7 million in 2025, then tumbled by 51.21% to -$184.0 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$184.0 million in Q1 2026, -$121.7 million in Q4 2025, and -$179.5 million in Q3 2025.